Internal restructuring
European Union
Location of affected unit(s)
France, Germany
Professional Services
Scientific, Architectural And Engineering Technical Activities
Scientific Research And Development
72 - Scientific research and development

466 jobs
Number of planned job losses
Job loss
Announcement Date
19 June 2019
Employment effect (start)
1 July 2019
Foreseen end date
31 March 2020


The French pharmaceutical giant Sanofi has announced a restructuring plan for its R&D activities that will result in 466 jobs cuts by early 2020, including 299 in France and 167 in Germany. Sanofi wants to redirect its activities in the strategic areas of oncology, immunology, rare diseases and vaccines. Sanofi currently has nearly 4,000 research and development employees in France and 1,500 in Germany, out of a total of 15,000 worldwide in this type of activity.

The plan was presented to employee representatives at a central social and economic committee of the research and development division. Negotiations are expected to take a few months for the plan to be implemented in late 2019 or early 2020. The group has cut positions in France in the last years: in 2016 (657 jobs), 2014 (200 jobs), 2012 (270 jobs) and recently in March 2019 (232 jobs). A worldwide restructuring was recorded in 2011 (1,400 to 3,000 job cuts in R&D, announced in 2011).



Eurofound (2019), Sanofi Aventis Groupe, Internal restructuring in European Union, factsheet number 98065, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/98065.